IA
AKRO

IndexIQ Advisors’s Akero Therapeutics AKRO Stock Holding History

IndexIQ Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,557
Closed -$308K – 1311
2021
Q4 		$308K Sell
14,557
-941
-6% -$20.9K 0.01% 931
2021
Q3 		$346K Buy
15,498
+1,552
+11% +$35.1K 0.01% 925
2021
Q2 		$346K Sell
13,946
-186
-1% -$5.22K 0.01% 912
2021
Q1 		$410K Buy
+14,132
New +$428K 0.01% 515

Other funds holding AKRO

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return

IndexIQ Advisors's AKRO Position: Q1 2022 in Review

IndexIQ Advisors sold out of Akero Therapeutics (AKRO) in Q1 2022, closing a stake of 14,557 shares — an estimated $308K sold.

IndexIQ Advisors first reported a position in AKRO in Q1 2021 and held it in 4 quarters. The position peaked at $410K in Q1 2021. 103 funds tracked by Wall St. Rank hold AKRO as of Q1 2022.

  • IndexIQ Advisors reported no remaining Akero Therapeutics position as of Q1 2022 after selling out during the quarter.
  • IndexIQ Advisors sold 14,557 Akero Therapeutics shares in Q1 2022, an estimated $308K.
  • IndexIQ Advisors first reported a position in Akero Therapeutics in Q1 2021 and held it in 4 quarters.
  • IndexIQ Advisors's Akero Therapeutics position peaked at $410K in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.